This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Sep 2020

Sympfiny® acceptability study among young children with positive results

Scientists at the University of Birmingham, UK have evaluated Sympfiny® as device for orally dispensing multiparticulate drugs to children aged 4-12.

Sympfiny® - developed in collaboration by Röchling Medical and HS Design - is an innovative system for dosing and delivering multiparticulate, dry powder, and microsphere drug formulations for oral delivery.

Scientists at the University of Birmingham, UK have now evaluated Sympfiny® as device for orally dispensing multiparticulate drugs to children aged 4-12 - with positive results.

The study published in „Pharmaceutics“ in August 2020 confirmed that with Sympfiny®, taste-masked, multiparticulate drugs can be administered to young children conveniently directly to the mouth without the need for using a co-administration vehicle such as food or drink.

Sympfiny was found particularly suitable for a lower dose range (0.1ml).

Read the full article here: https://www.mdpi.com/1999-4923/12/9/806

Mentioned Companies
Röchling Medical Solutions SE
View company profile